Evidence map›Paper›PMID 41922364›Full record

ArticleNature communications2026

Accelerated drug development using a digital formulator and a self-driving tableting data factory.

Faisal Abbas, Mohammad Salehian, Peter Hou, Jonathan Moores, Jonathan Goldie, Alexandros Tsioutsios, Theo Tait, Victor Portela, Quentin Boulay, Roland Thiolliere and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Faisal Abbas *CMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.ORCID http://orcid.org/0000-0003-2323-278X
Mohammad Salehian *CMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.ORCID http://orcid.org/0000-0003-4073-292X
Peter HouCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.ORCID http://orcid.org/0000-0001-5166-8869
Jonathan MooresCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.ORCID http://orcid.org/0009-0004-7119-0347
Jonathan GoldieCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.
Alexandros TsioutsiosCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.ORCID http://orcid.org/0009-0006-7633-4666
Theo TaitCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.ORCID http://orcid.org/0009-0004-6891-3794
Victor PortelaGlasgow School of Art, Glasgow, UK.ORCID http://orcid.org/0000-0001-9636-6573
Quentin BoulayMedelpharm, ZAC des Malettes, Beynost, France.
Roland ThiolliereMedelpharm, ZAC des Malettes, Beynost, France.
Ashley StarkDEC Group, Chemin du Dévent 3, Ecublens, Switzerland.
Jean-Jacques SchwartzDEC Group, Chemin du Dévent 3, Ecublens, Switzerland.ORCID http://orcid.org/0009-0004-7879-2877
Jerome GuerinDEC Group, Chemin du Dévent 3, Ecublens, Switzerland.
Andrew G P MaloneyThe Cambridge Crystallographic Data Centre, Cambridge, UK.ORCID http://orcid.org/0000-0002-2578-9293
Alexandru A MoldovanThe Cambridge Crystallographic Data Centre, Cambridge, UK.ORCID http://orcid.org/0000-0003-2776-3879
Gavin K ReynoldsSustainable Innovation & Transformational Excellence (xSITE), Pharmaceutical Technology & Development, Operations, AstraZeneca UK Limited, Macclesfield, UK.ORCID http://orcid.org/0000-0002-9592-8228
Jérôme MantanusUCB S.A, 60 Allée de la Recherche, Brussels, Belgium.
Catriona ClarkCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.
Paul ChapmanGlasgow School of Art, Glasgow, UK.ORCID http://orcid.org/0000-0002-6390-5558
Alastair FlorenceCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.ORCID http://orcid.org/0000-0002-9706-8364
Daniel MarklCMAC, Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK. daniel.markl@strath.ac.uk.ORCID http://orcid.org/0000-0003-0411-733X

Funding

RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/P006965/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/R032858/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/V062077/1
6 · The paper itself

Abstract

Advances in drug discovery and clinical research have shifted the bottleneck in medicines development to chemistry, manufacturing, and controls activities, a critically step for regulatory approval. This includes formulation and process development of a new drug product, which traditionally requires extensive resources, often leading to suboptimal outcomes. These development processes must adapt to follow the advances in drug discovery and clinical research and ultimately shorten timelines while ensuring product quality and safety. In this work, we present an integrated platform for tablet formulation and process development that couples a digital formulator, an in-silico optimisation tool using a predictive material-to-tablet model, with a self-driving tableting data factory, which applies Bayesian optimisation within an automated, fully integrated per-tablet manufacturing to testing workflow. The results demonstrate a reduction in the time from material characterisation to in-specification tablets to 6 h and a reduction in API material use by 65% compared to current state-of-the-art methods.

Indexed as

Drug DevelopmentTabletsBayes TheoremBulk DrugsChemistry, PharmaceuticalComputer SimulationDrug DiscoveryBulk DrugsTablets

Identifiers

PMID41922364
PMCPMC13216267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.